KEYTRUDA® (pembrolizumab) in cervical cancer resources
Prescribing Information [External link]
KEYTRUDA, in combination with chemotherapy with or without bevacizumab, is indicated for the treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD‑L1 with a combined positive score (CPS) ≥1.
For more information about KEYTRUDA in cervical cancer explore our product page
Please refer to Summary of Product Characteristics for full list of AEs and management.
KEYTRUDA® (pembrolizumab) in endometrial cancer resources
Prescribing Information [External link]
KEYTRUDA, in combination with lenvatinib, is indicated for the treatment of advanced or recurrent endometrial carcinoma in adults who have disease progression on or following prior treatment with a platinum-containing therapy in any setting, and who are not candidates for curative surgery or radiation.
For more information about KEYTRUDA in endometrial cancer explore our product page
Please refer to Summary of Product Characteristics for full list of AEs and management.
Patient assets
Please be aware you should not direct patients to this website. You should download the diary on their behalf and share it with them as appropriate.
🖨️
To order printed versions of these diaries to your place of work, please contact:
msdukoncology@msd.com
Supporting documentation
Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.
